Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Camillo Mendoza

Internal Medicine Brazil, IN Medical Doctor

NPI 1023081395 CMS profile 46092

1011 E National Ave, Brazil, IN 47834

Open in the dashboard

General payments

$11,518

667 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Camillo Mendoza of Brazil, IN is reported in the CMS Open Payments database as having received $11,518 across 667 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,517 89
2024 General $2,719 121
2023 General $1,925 118
2022 General $2,031 126
2021 General $1,473 99
2020 General $354 25
2019 General $1,500 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Camillo Mendoza
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Camillo Mendoza were reported at $1,517. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Camillo Mendoza Internal Medicine median Middle half National median
2019 $1,500 $159 $48–$570 $163
2020 $354 $119 $33–$402 $114
2021 $1,473 $135 $37–$521 $132
2022 $2,031 $141 $42–$496 $149
2023 $1,925 $149 $45–$519 $160
2024 $2,719 $154 $47–$537 $164
2025 $1,517 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,474 87 payments
  2. Novo Nordisk Inc $957 81 payments
  3. AbbVie, Inc. $842 46 payments
  4. Lilly USA, LLC $823 62 payments
  5. Amgen Inc. $672 31 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $609 33 payments
  7. Teva Pharmaceuticals USA, Inc. $589 61 payments
  8. Janssen Pharmaceuticals, Inc $530 27 payments
  9. Pfizer Inc. $510 27 payments
  10. Novartis Pharmaceuticals Corporation $500 34 payments
  11. Other $3,011 178 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,358 658 payments
  2. Education $160 9 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,706 53 payments
  2. Kerendia $609 33 payments
  3. XARELTO $530 27 payments
  4. AIRSUPRA $526 15 payments
  5. VRAYLAR $438 24 payments
  6. BREZTRI $438 20 payments
  7. AJOVY $433 44 payments
  8. Repatha $407 20 payments
  9. Ozempic $385 36 payments
  10. RYBELSUS $370 35 payments
  11. Other $8,327 537 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 256 drugs

Part D claims

26,060

Median for Internal Medicine: 777

Drug cost

$1,914,280

Median for Internal Medicine: $73,373

Branded share of claims

21.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 497 $227,273
Ozempic Semaglutide Brand 149 $164,761
Jardiance Empagliflozin Brand 205 $149,856
Farxiga Dapagliflozin Propanediol Brand 172 $135,623
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 98 $83,431
Xarelto Rivaroxaban Brand 145 $75,646
Mounjaro Tirzepatide Brand 52 $66,250
Rybelsus Semaglutide Brand 56 $64,852
Januvia Sitagliptin Phosphate Brand 65 $56,608
Trulicity Dulaglutide Brand 41 $43,719

The 10 drugs with the highest cost, of 256 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$131,995

Medicare's payments for the services billed

Medicare patients

659

Average age 77

Services billed

2,174

355 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 52%
Arthritis 49%
Diabetes 46%
Ischemic heart disease 45%
Depression 32%
Heart failure 31%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $438
$438 172 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $296
$296 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $222
$222 145 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $217
$217 14 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $189
$189 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

667 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record